Topical application of nerve labeling dyes for image-guided surgery
AssigneeGeneral Electric Company
InventorsCristina Abucay Tan Hehir, Tiberiu Mircea Siclovan, Victoria Eugenia Cotero
Life of this patent
Estimating the term…
Abstract
The present invention relates to a topical agent that binds specifically to myelin basic protein and its method of use and determining myelination in the subject by detecting the agent present in the subject. A kit containing the agent or its derivatives for use in detecting myelin basic protein is also provided.
Claims30
A pharmaceutical agent comprising:
- a syringe;
- a compound of Formula I or a salt thereof, wherein Formula I is:
- wherein R1 is an alkyl group, R2 is an electron donating group and R3 is an electron withdrawing group;
- and
- an aqueous pharmaceutical carrier, wherein the compound of Formula I and the aqueous pharmaceutical carrier are disposed in the syringe, wherein the aqueous pharmaceutical carrier comprises, based on volume:
- 1-30% PEG-300, 1-20% propylene glycol and 1-10% polyvinylpyrrolidone.
A method of imaging myelin basic protein in an open or minimally invasive surgical field by intravenous (IV) injection administration of a pharmaceutical agent comprising the steps of:
- intravenously injecting a subject with the pharmaceutical agent, the pharmaceutical agent comprising a compound of Formula I or a salt thereof, wherein Formula I is:
- wherein R1 is an alkyl group, R2 is an electron donating group and R3 is an electron withdrawing group;
- and
- an aqueous pharmaceutical carrier, wherein the aqueous pharmaceutical carrier comprises, based on volume:
- 1-30% PEG-300, 1-20% propylene glycol and 1-10% polyvinylpyrrolidone;
- detecting the pharmaceutical agent by applying a light source tuned to one or more spectral excitation characteristics of the agent;
- and
- observing the subject through an optical filter tuned to the spectral emission characteristics of the agent.
A kit for providing an intravenous (IV) injection administered pharmaceutical agent comprising:
- a syringe;
- a compound of Formula I or a salt thereof, wherein Formula I is:
- wherein R1 is an alkyl group, R2 is an electron donating group and R3 is an electron withdrawing group;
- and
- an aqueous pharmaceutical carrier, wherein the aqueous pharmaceutical carrier comprises, based on volume:
- 1-10% polyvinylpyrrolidone and at least one other solvent.
Dependencies are inferred from the claim text.